Q1 EPS Estimates for Neuronetics Increased by William Blair

Neuronetics, Inc. (NASDAQ:STIM) – Equities research analysts at William Blair boosted their Q1 2025 EPS estimates for Neuronetics in a research report issued to clients and investors on Wednesday, March 5th. William Blair analyst M. Andrew now forecasts that the company will post earnings of ($0.15) per share for the quarter, up from their prior estimate of ($0.25). The consensus estimate for Neuronetics’ current full-year earnings is ($1.13) per share. William Blair also issued estimates for Neuronetics’ Q2 2025 earnings at ($0.08) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.02) EPS, FY2025 earnings at ($0.35) EPS, Q1 2026 earnings at ($0.13) EPS, Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at ($0.10) EPS, Q4 2026 earnings at ($0.02) EPS and FY2026 earnings at ($0.33) EPS.

Separately, Canaccord Genuity Group boosted their target price on shares of Neuronetics from $5.00 to $8.00 and gave the company a “buy” rating in a research report on Wednesday.

Neuronetics Trading Up 2.2 %

Shares of Neuronetics stock opened at $5.07 on Friday. The firm has a 50-day moving average of $3.21 and a 200-day moving average of $1.75. The stock has a market cap of $153.86 million, a PE ratio of -4.12 and a beta of 2.07. Neuronetics has a 52-week low of $0.52 and a 52-week high of $5.92. The company has a debt-to-equity ratio of 4.90, a quick ratio of 2.87 and a current ratio of 3.16.

Insider Buying and Selling

In related news, CEO Keith J. Sullivan sold 40,992 shares of the company’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $3.28, for a total transaction of $134,453.76. Following the completion of the sale, the chief executive officer now owns 1,283,362 shares of the company’s stock, valued at $4,209,427.36. This represents a 3.10 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Stephen Furlong sold 10,845 shares of the company’s stock in a transaction dated Wednesday, February 12th. The stock was sold at an average price of $3.83, for a total transaction of $41,536.35. Following the sale, the chief financial officer now directly owns 471,727 shares of the company’s stock, valued at $1,806,714.41. This represents a 2.25 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 100,369 shares of company stock valued at $358,929 over the last quarter. 9.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of STIM. Balyasny Asset Management L.P. raised its stake in Neuronetics by 29.5% during the fourth quarter. Balyasny Asset Management L.P. now owns 1,481,771 shares of the company’s stock worth $2,386,000 after acquiring an additional 337,539 shares in the last quarter. HighTower Advisors LLC raised its stake in Neuronetics by 55.5% during the third quarter. HighTower Advisors LLC now owns 245,982 shares of the company’s stock worth $187,000 after acquiring an additional 87,816 shares in the last quarter. Landscape Capital Management L.L.C. acquired a new position in Neuronetics during the third quarter worth about $53,000. JPMorgan Chase & Co. raised its stake in Neuronetics by 10,954.1% during the fourth quarter. JPMorgan Chase & Co. now owns 54,939 shares of the company’s stock worth $88,000 after acquiring an additional 54,442 shares in the last quarter. Finally, GSA Capital Partners LLP raised its stake in Neuronetics by 64.5% during the third quarter. GSA Capital Partners LLP now owns 78,642 shares of the company’s stock worth $60,000 after acquiring an additional 30,837 shares in the last quarter. Institutional investors and hedge funds own 53.59% of the company’s stock.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.